Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2014. The report details a specific corporate action regarding the repurchase of the company's own shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The financial information is limited to share repurchase activity and capital structure metrics:
- Shares Purchased: 575,000 Ordinary Shares on June 11, 2014.
- Price Range: Highest price paid was 1,620 pence per share; lowest price paid was 1,606.50 pence per share.
- Treasury Holdings (Settled): 499,547,414 shares (9.34% of total issued share capital).
- Treasury Holdings (Including Unsettled): 500,747,414 shares (10.32% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,851,302,291 shares.
Material Changes
The primary material change reported is the increase in the company's treasury share holdings following the purchase of 575,000 shares. This transaction slightly increased the percentage of total voting rights held in treasury from 9.34% to 10.32% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming the execution of a share buyback program and adherence to the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares held in treasury (499,547,414 settled) against the company's latest capitalization table.
- Confirm the impact of the 10.32% treasury holding on the denominator for shareholder notification thresholds under FCA rules.
- Note that this filing does not contain operational or financial performance data for the period; refer to Form 20-F for comprehensive financial statements.